Robert Cunningham
Ophthalmology · East Orange, NJNPI 1306855861
Payments from drug & device makers
Across 87 payments — averaging $26.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$546
- AbbVie$436
- Aerie Pharmaceuticals, Inc.$350
- Sight Sciences, Inc.$166
- Bausch & Lomb, A Division Of Bausch Health US, LLC$162
- Novartis$136
- plus $527 from 12 others
What the payments were for
- Food & beverage$2,323100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,323 in reported general payments places this provider in the 60th percentile of 583 ophthalmology providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 35 | $30,878 |
| LumiganBimatoprost | 23 | $9,455 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $5,410 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $4,781 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 30 | $3,852 |
| Prednisolone Acetate | 48 | $1,748 |
| Ketorolac Tromethamine | 51 | $1,631 |
| Brimonidine Tartrate | 29 | $1,266 |
| Latanoprost | 146 | $923 |
| Dorzolamide Hcl | 15 | $313 |
| Ciprofloxacin Hcl | 22 | $278 |
| Timolol Maleate | 44 | $276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $128 | $30,87835 claims |
| AbbVieLumigan, Combigan | $436 | $14,86635 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $350 | $4,78113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in East Orange
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Charles CraneSouth Orange$582K
- Albert KhouriNewark$542K
- Brett BieloryRutherford$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.